Kamal Hamed - Feb 1, 2024 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Chief Medical Officer
Signature
/s/ Tamara Joseph. Attorney-in-Fact for Kamal Hamed
Stock symbol
SPRO
Transactions as of
Feb 1, 2024
Transactions value $
-$38,463
Form type
4
Date filed
2/5/2024, 08:45 PM
Previous filing
Sep 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +240K +41.59% $0.00 816K Feb 1, 2024 Direct F1
transaction SPRO Common Stock Sale -$38.5K -28.1K -3.44% $1.37 788K Feb 2, 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
F2 The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023 pursuant to a "sell to cover" provision included in the RSU Agreement.
F3 Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.